The University of Sydney School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Australia.
Res Social Adm Pharm. 2022 Mar;18(3):2529-2537. doi: 10.1016/j.sapharm.2021.03.011. Epub 2021 Mar 26.
Globally, the availability and delivery of cognitive pharmaceutical services (CPS) by pharmacists has expanded over time. Australia has been no exception to this trend, with government funding to support the provision of certain CPS significantly increasing over the last two decades. Whilst medication management services have been consistently funded by the government for more than 15 years, fluctuations in the funding of other CPS have been observed; for example, certain disease state management CPS and introduction of funded MedsChecks. Furthermore, legislative changes have broadened pharmacists' scope of practice and the CPS provided, contributing to an increase in user-pay services. Although the literature to date has highlighted positive impacts associated with CPS on economic, clinical and/or humanistic outcomes, context-specific, real world evidence for the benefits of CPS is much needed to ensure the profession engages in evidence-based practice. The aim of this commentary is to outline the changes in CPS provision and funding within the Australian context, the existing evidence for CPS, and highlight the implications for future research.
从全球范围来看，药剂师提供认知药物服务（CPS）的可及性和提供情况随着时间的推移而不断扩大。澳大利亚也不例外，在过去的二十年中，政府为支持提供某些 CPS 提供了大量资金。虽然药物管理服务已经得到政府超过 15 年的持续资助，但其他 CPS 的资助情况却存在波动；例如，某些疾病管理 CPS 和引入的付费 MedsChecks。此外，立法改革拓宽了药剂师的实践范围和提供的 CPS，这导致用户付费服务的增加。尽管迄今为止的文献强调了 CPS 在经济、临床和/或人文结果方面的积极影响，但为了确保该专业开展循证实践，非常需要针对 CPS 益处的具体情况、真实世界的证据。本评论的目的是概述澳大利亚 CPS 提供和资助方面的变化、CPS 的现有证据，并强调对未来研究的影响。
